Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice

Journal of Clinical Investigation

Volumn 118, Issue 11, 2008, Pages 3588-3597

  Montgomery, Rusty L ^a   Potthoff, Matthew J ^a   Haberland, Michael ^a   Qi, Xiaoxia ^a   Matsuzaki, Satoshi ^b   Humphries, Kenneth M ^b   Richardson, James A ^a,c   Bassel Duby, Rhonda ^a   Olson, Eric N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 3; ISOPRENALINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON TRANSPORT; ENERGY METABOLISM; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE CONTROL; GENE DELETION; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL;

ANIMALS; CARDIOMEGALY; ENERGY METABOLISM; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART; HISTONE DEACETYLASES; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; PPAR ALPHA; UP-REGULATION;

EID: 55849084700     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35847     Document Type: Article

References (51)

1. Gardin, J.M., and Lauer, M.S. 2004. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 292:2396-2398.
2. Devereux, R.B., et al. 2004. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292:2350-2356.
3. Okin, P.M., et al. 2004. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 292:2343-2349.
4. Hill, J.A., and Olson, E.N. 2008. Cardiac plasticity. N. Engl. J. Med. 358:1370-1380.
5. Olson, E.N., and Schneider, M.D. 2003. Sizing up the heart: development redux in disease. Genes Dev. 17:1937-1956.
6. Frey, N., and Olson, E.N. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65:45-79.
7. McKinsey, T.A., and Olson, E.N. 2005. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. 115:538-546.
8. Jenuwein, T., and Allis, C.D. 2001. Translating the histone code. Science. 293:1074-1080.
9. Roth, S.Y., Denu, J.M., and Allis, C.D. 2001. Histone acetyltransferases. Annu. Rev. Biochem. 70:81-120.
10. McKinsey, T.A., and Olson, E.N. 2004. Cardiac histone acetylation - therapeutic opportunities abound. Trends Genet. 20:206-213.
11. McKinsey, T.A., Zhang, C.L., Lu, J., and Olson, E.N. 2000. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 408:106-111.
12. Zhang, C.L., et al. 2002. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:479-488.
13. Antos, C.L., et al. 2003. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278:28930-28937.
14. Kee, H.J., et al. 2006. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 113:51-59.
15. Kong, Y., et al. 2006. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 113:2579-2588.
16. Grozinger, C.M., and Schreiber, S.L. 2002. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9:3-16.
17. Montgomery, R.L., et al. 2007. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21:1790-1802.
18. Trivedi, C.M., et al. 2007. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 13:324-331.
19. Guenther, M.G., Barak, O., and Lazar, M.A. 2001. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol. Cell. Biol. 21:6091-6101.
20. Sakai, K., and Miyazaki, J. 1997. A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. Biochem. Biophys. Res. Commun. 237:318-324.
21. Agah, R., et al. 1997. Gene recombination in post-mitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo. J. Clin. Invest. 100:169-179.
22. Gui, C.Y., Ngo, L., Xu, W.S., Richon, V.M., and Marks, P.A. 2004. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U. S. A. 101:1241-1246.
23. Huss, J.M., and Kelly, D.P. 2004. Nuclear receptor signaling and cardiac energetics. Circ. Res. 95:568-578.
24. Finck, B.N., et al. 2002. The cardiac phenotype induced by PPAR? overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109:121-130.
25. Young, M.E., et al. 2001. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J. 15:833-845.
26. Stanley, W.C., Lopaschuk, G.D., and McCormack, J.G. 1997. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 34:25-33.
27. Glyn-Jones, S., et al. 2007. Transcriptomic analysis of the cardiac left ventricle in a rodent model of diabetic cardiomyopathy: molecular snapshot of a severe myocardial disease. Physiol. Genomics. 28:284-293.
28. Murthy, V.K., and Shipp, J.C. 1977. Accumulation of myocardial triglycerides ketotic diabetes; evidence for increased biosynthesis. Diabetes. 26:222-229.
29. Boudina, S., and Abel, E.D. 2007. Diabetic cardiomyopathy revisited. Circulation. 115:3213-3223.
30. Boudina, S., and Abel, E.D. 2006. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda). 21:250-258.
31. Cocco, T., Di Paola, M., Papa, S., and Lorusso, M. 1999. Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation. Free Radic. Biol. Med. 27:51-59.
32. Loskovich, M.V., Grivennikova, V.G., Cecchini, G., and Vinogradov, A.D. 2005. Inhibitory effect of palmitate on the mitochondrial NADH:ubiquinone oxidoreductase (complex I) as related to the active-de-active enzyme transition. Biochem. J. 387:677-683.
33. Schonfeld, P., and Reiser, G. 2006. Rotenone-like action of the branched-chain phytanic acid induces oxidative stress in mitochondria. J. Biol. Chem. 281:7136-7142.
34. Guan, H.P., Ishizuka, T., Chui, P.C., Lehrke, M., and Lazar, M.A. 2005. Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes. Genes Dev. 19:453-461.
35. Fajas, L., et al. 2002. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev. Cell. 3:903-910.
36. Kersten, S., et al. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103:1489-1498.
37. Watanabe, K., et al. 2000. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J. Biol. Chem. 275:22293- 22299.
38. Cheng, L., et al. 2004. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10:1245-1250.
39. Burkart, E.M., et al. 2007. Nuclear receptors PPAR-beta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117:3930-3939.
40. Huss, J.M., Torra, I.P., Staels, B., Giguere, V., and Kelly, D.P. 2004. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24:9079-9091.
41. Villagra, A., et al. 2007. Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. J. Biol. Chem. 282:35457-35470.
42. Fischle, W., et al. 2002. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell. 9:45-57.
43. Gregoire, S., et al. 2007. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol. Cell. Biol. 27:1280-1295.
44. Kim, Y., et al. 2008. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J. Clin. Invest. 118:124-132.
45. Duvic, M., et al. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 109:31-39.
46. van Rooij, E., et al. 2008. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105:13027-13032.
47. van Rooij, E., et al. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 103:18255-18260.
48. Davis, C.A., et al. 2006. PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells. Mol. Cell. Biol. 26:2626-2636.
49. Nelson, J.D., Denisenko, O., Sova, P., and Bomsztyk, K. 2006. Fast chromatin immunoprecipitation assay. Nucleic Acids Res. 34:e2.
50. Yu, X., et al. 2007. Early myocardial dysfunction in streptozotocin- induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc. Diabetol. 6:6.
51. Knutson, S.K., et al. 2008. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 27:1017-1028.